Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab

 
• By Alexandra Shimmings

Novartis is taking its unexpected CANTOS cancer findings for canakinumab and running with them to Phase III in an adjuvant lung cancer setting that is broader that AstraZeneca's PACIFIC study.

Highway
Canakinumab Takes the Pacific Highway • Source: Shutterstock

More from Clinical Trials

More from R&D